Comparable Efficacy and Safety of Brodalumab in Obese and Non-Obese Patients With Psoriasis: Analysis of 2 Randomized Controlled Trials.

Obesity is associated with psoriasis and negatively affects response to therapy.To evaluate efficacy and safety of brodalumab in non-obese vs obese patients with psoriasis.

In this post hoc analysis of the prospective, phase 3, multicentre, randomized, placebo- and active comparator-controlled AMAGINE-2 and AMAGINE-3 trials, patients were randomized to treatment with brodalumab 210 mg every 2 weeks, ustekinumab, or placebo for a 12-week induction phase. At week 12, patients who received brodalumab 210 mg Q2W continued brodalumab, those treated with ustekinumab continued ustekinumab, and those who received placebo switched to brodalumab 210 mg every 2 weeks. Patients were categorized by body mass index (BMI) category (<30 kg/m² or ≥30 kg/m² ) and efficacy was evaluated using the physician-rated psoriasis area and severity index and static physician's global assessment instruments.

In total, 281 of 687 patients (40.9%) were obese. Skin clearance was comparable across body mass index subgroups in brodalumab-treated patients. Psoriasis area and severity index 100% improvement rates in non-obese and obese patients at week 12 were 54.1% and 49.5%, respectively, and at week 52 were 72.6% and 64.8%, respectively. Week 12 ustekinumab responses were lower than brodalumab responses and were 6% to 17% lower in obese than in non-obese patients. No appreciable differences in overall safety were observed between non-obese and obese patients.

Efficacy and safety of brodalumab did not differ between patients with moderate-to-severe psoriasis who had a BMI <30 kg/m² and a BMI ≥30 kg/m² . This article is protected by copyright. All rights reserved.